# Therasphere for Unresectable Primary or Secondary Liver Neoplasia

> **NCT02960620** · — · NO_LONGER_AVAILABLE · sponsor: **H. Lee Moffitt Cancer Center and Research Institute**

## Conditions studied

- Liver Cancer
- Liver Neoplasms
- HepatoCellular Carcinoma

## Interventions

- **DEVICE:** TheraSphere Treatment

## Key facts

- **NCT ID:** NCT02960620
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-09-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960620, "Therasphere for Unresectable Primary or Secondary Liver Neoplasia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02960620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*